Benign prostatic hyperplasia

被引:274
作者
Thorpe, A
Neal, D
机构
[1] Addenbrookes Hosp, Dept Surg, Ctr Oncol, Cambridge CB2 2QQ, England
[2] Addenbrookes Hosp, Dept Canc Res, Ctr Oncol, Cambridge CB2 2QQ, England
[3] Freeman Rd Hosp, Dept Urol, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England
关键词
D O I
10.1016/S0140-6736(03)13073-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In both ageing men and women, lower urinary tract symptoms (LUTS) are increasing. These infections have many possible causes, including smooth muscle dysfunction, neurological factors and benign prostatic hyperplasia. Up to 15% to 25% of men aged 50-65 years have LUTS of sufficient severity to interfere with their quality of life. Although benign prostatic hyperplasia is an important cause of these symptoms, and can have serious consequences, clinicians should be aware of these other causes so that the appropriate diagnosis Is made before invasive treatments are started. New medical treatments, Including alpha-adrenergic blocking agents and 5 alpha-reductase inhibitors mean that many men without complications such as infection, bleeding, or chronic retention, and with mild to moderate symptoms, should be managed in primary care. Combined local protocols between primary and secondary care will help to establish which men with persistent symptoms or complications need referral for a urological opinion to determine the need for further investigation and more invasive forms of management. We review the pathophysiology of the disease, and current approaches to investigation and management of this common problem.
引用
收藏
页码:1359 / 1367
页数:9
相关论文
共 127 条
[1]  
Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052
[2]  
ABRAMS P, 1978, URODYNAMIC FINDINGS, P1258
[3]   SIGNIFICANCE OF SYMPTOMS ASSOCIATED WITH BLADDER OUTFLOW OBSTRUCTION [J].
ABRAMS, PH ;
FENELEY, RCL .
UROLOGIA INTERNATIONALIS, 1978, 33 (1-3) :171-174
[4]  
[Anonymous], 2000, EUR UROL, V37, P680
[5]   Impact of interventional therapy for benign prostatic hyperplasia on quality of life and sexual function: A prospective study [J].
Arai, Y ;
Aoki, Y ;
Okubo, K ;
Maeda, H ;
Terada, N ;
Matsuta, Y ;
Maekawa, S ;
Ogura, K .
JOURNAL OF UROLOGY, 2000, 164 (04) :1206-1211
[6]   HIGH-RISK GROUP FOR BENIGN PROSTATIC HYPERTROPHY [J].
ARAKI, H ;
WATANABE, H ;
MISHINA, T ;
NAKAO, M .
PROSTATE, 1983, 4 (03) :253-264
[7]  
BARRY MJ, 1990, PROSTATE, P61
[8]  
BARRY MJ, 1990, UROL CLIN N AM, V17, P495
[9]   Dihydrotestosterone and the concept of 5α-reductase inhibition in human benign prostatic hyperplasia [J].
Bartsch, G ;
Rittmaster, RS ;
Klocker, H .
EUROPEAN UROLOGY, 2000, 37 (04) :367-380
[10]   THE DEVELOPMENT OF HUMAN BENIGN PROSTATIC HYPERPLASIA WITH AGE [J].
BERRY, SJ ;
COFFEY, DS ;
WALSH, PC ;
EWING, LL .
JOURNAL OF UROLOGY, 1984, 132 (03) :474-479